{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:21:51Z","timestamp":1780446111740,"version":"3.54.1"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100014584","name":"Ignyta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014584","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Head &amp; Neck"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The efficacy of entrectinib, a potent inhibitor of tropomyosin receptor kinases, c\u2010ros oncogene 1, and anaplastic lymphoma kinase has been demonstrated in neurotrophic receptor tyrosine kinase fusion\u2010positive pediatric and adult solid tumors. However, real\u2010world data on entrectinib therapy for salivary gland malignancies are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We describe a multicenter case series of four consecutive patients with <jats:italic>ETV6\u2010NTRK3<\/jats:italic> fusion\u2010positive metastatic salivary secretory carcinoma (SSC) treated with entrectinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patients had a prior history of systemic therapy with cytotoxic chemotherapy or immune checkpoint inhibitors. All patients achieved durable radiographic complete response. Adverse events included weight gain, dizziness, increase in creatine kinase level, and withdrawal pain, but were manageable by the interruption and dose reduction of entrectinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Durable complete response was achieved with entrectinib in patients with <jats:italic>ETV6\u2010NTRK3<\/jats:italic> fusion\u2010positive metastatic SSC. The clinical benefit of entrectinib supports the importance of routine screening for <jats:italic>NTRK<\/jats:italic> gene fusion in patients with SSC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hed.27346","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T08:38:49Z","timestamp":1678955929000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real\u2010world experience of tropomyosin receptor kinase inhibition with entrectinib in <scp><i>ETV6\u2010NTRK3<\/i><\/scp> positive metastatic salivary secretory carcinoma: A case series"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-7949","authenticated-orcid":false,"given":"Tomoya","family":"Yokota","sequence":"first","affiliation":[{"name":"Division of Gastrointestinal Oncology Shizuoka Cancer Center  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yukino","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery Kyorin University School of Medicine  Mitaka Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Doi","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine and Clinical Oncology Hiroshima Prefectural Hospital  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatsugu","family":"Ohori","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Japanese Red Cross Ishinomaki Hospital  Miyagi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2009.10.004"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000980"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000322"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181d9efcc"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00064"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S147381"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac087"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30856-3"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2022.2523"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040290"},{"key":"e_1_2_6_13_1","article-title":"The experience of successful treatment of ETV6\u2010NTRK3\u2010positive infant glioblastoma with entrectinib","volume":"3","author":"Papusha L","year":"2021","journal-title":"Neurooncol Adv"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.7029"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-017-0009-y"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JTO.0000473485.38553.f0"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.006"},{"key":"e_1_2_6_18_1","first-page":"418","article-title":"Larotrectinib and Entrectinib: TRK inhibitors for the treatment of pediatric and adult patients with NTRK gene fusion","volume":"11","author":"Dunn DB","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz282"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1309091"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0596"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0542-z"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0909"}],"container-title":["Head &amp; Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.27346","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hed.27346","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.27346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T23:46:05Z","timestamp":1692488765000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.27346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/hed.27346"],"URL":"https:\/\/doi.org\/10.1002\/hed.27346","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"2022-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}